ki:elements speech biomarker for cognition
Measuring cognition through a scalable speech biomarker
The ki:e SB-C is based on speech recordings from two gold standard cognitive tests (Semantic Verbal Fluency and Rey Auditory Verbal Learning task) that take 10-15 minutes to perform. More than 120 features are automatically extracted from the recordings and combined into a cognitive composite and three sub-scales measuring executive function, episodic memory, and processing speed.
It has applicability to the following disease areas:
- Alzheimer’s disease
- Parkinson’s disease
- Schizophrenia
- Multiple sclerosis
- Mild Cognitive Impairment
- …
A valid clinical measure
Compiling validation evidence in an evidence dossier
The SB-C has been validated in multiple studies to show relation to existing measures (i.e., MMSE, CDR), its test-retest reliability and its ability to detect clinically meaningful differences. The full validation evidence is compiled in an evidence dossier according to scientific standards (DIME, Walton 2020).
Correlation with the MMSE
Strong correlation of the ki:e SB-C biomarker with MMSE total score.
Discriminating between stages
Significant group differences between Dementia, MCI and HC.
SB-C in action
Measuring cognition in different applications in and around trials
SB-C can be used for multiple different applications in and around trials. It’s a valid measure to track cognition and can be used as a decentralized assessment tool. SB-C can also be used to screen participants for Mild cognitive impairment (MCI), e.g., as a pre-screener for trial recruitment.
MMSE
ki:e SB-C
Use SB-C in your study!
Get in touch
We’re looking forward to working with you! SB-C is deployed via our Mili platform into clinical studies and trials. If you are interested in deploying it in your study, please reach out to us.
Academic groups wanting to use the technology can partner with us to receive reduced licensing costs.